Congenital heart disease and pulmonary hypertension: Pharmacology and feasibility of late surgery

Progress in Cardiovascular Diseases

Volumn 55, Issue 2, 2012, Pages 128-133

  Rosenzweig, Erika B ^a   Barst, Robyn J ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Congenital heart disease; Operability; Pulmonary hypertension; Pulmonary vascular disease; Vasodilator therapy

Indexed keywords

AMBRISENTAN; BOSENTAN; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; SILDENAFIL;

ANATOMICAL VARIATION; ARTICLE; CLINICAL EFFECTIVENESS; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EISENMENGER COMPLEX; FEASIBILITY STUDY; HEART CATHETERIZATION; HEART HEMODYNAMICS; HUMAN; LUNG VASCULAR RESISTANCE; PHYSIOLOGICAL PROCESS; PULMONARY HYPERTENSION; SURGICAL APPROACH; TREATMENT DURATION; TREATMENT PLANNING;

CARDIAC SURGICAL PROCEDURES; FEASIBILITY STUDIES; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; TIME FACTORS; VASCULAR SURGICAL PROCEDURES; VASODILATOR AGENTS;

EID: 84866606631     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2012.07.004     Document Type: Article

References (15)

1. Rose M., Strange G., King I., et al. Congenital heart disease associated pulmonary arterial hypertension: preliminary results from a novel registry. Intern Med J 2011.
2. Gatzoulis M.A., Alonso-Gonzalez R., Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009, 18(113):154-161.
3. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53(17):1573-619.
4. Kidd L., Driscoll D.J., Gersony W.M., et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993, 87(2 Suppl):I38-I51.
5. Barst R.J. Primary pulmonary hypertension. In: Proceedings of the National Heart, Lung, and Blood Institute Pediatric Cardiology Workshop: Pulmonary Hypertension, Ed., Friedman WF. Pediatr Res 1986, 20:816-817.
6. Beghetti M., Galiè N., Bonnet D. Can "inoperable" congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality?. Congenit Heart Dis 2012, 7(1):3-11.
7. Simonneau G., Robbins I.M., Beghetti M. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-S54.
8. Simonneau G., Galiè N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):5S-12S.
9. Diller G.P., Dimopoulos K., Broberg C.S., et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006, 27(14):1737-1742.
10. Dimopoulos K., Inuzuka R., Goletto S., et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010, 121(1):20-25.
11. Diller G.P., Alonso-Gonzalez R., Dimopoulos K., et al. Disease targeting therapies in patients with Eisenmenger syndrome: Response to treatment and long-term efficiency. Int J Cardiol 2012, (epublished ahead of print: PMID 22390966).
12. Galiè N., Beghetti M., Gatzoulis M.A., et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114(1):48-54.
13. Zuckerman W.A., Leaderer D., Rowan C.A., Rosenzweig E.B., et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 2011, 107(9):1381-1385.
14. Zhang Z.N., Jiang X., Zhang R., et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 2011, 97(22):1876-1881.
15. Giglia T.M., Humpl T. Preoperative pulmonary cardiac operation?. Pediatr Crit Care Med 2010, 11(2 Suppl):S57-S69.